Xanthohumol (XN) is a natural anticancer compound that inhibits the proliferation of oestrogen receptor-a (ERa)-positive breast cancer cells. However, the precise mechanism of the antitumour effects of XN on oestrogen (E2)-dependent cell growth, and especially its direct target molecule(s), remain(s) largely unknown. Here, we focus on whether XN directly binds to the tumour suppressor protein prohibitin 2 (PHB2), forming a novel natural antitumour compound targeting the BIG3-PHB2 complex and acting as a pivotal modulator of E2/ERa signalling in breast cancer cells. XN treatment effectively prevented the BIG3-PHB2 interaction, thereby releasing PHB2 to directly bind to both nuclear-and cytoplasmic ERa. This event led to the complete suppression of the E2-signalling pathways and ERa-positive breast cancer cell growth both in vitro and in vivo, but did not suppress the growth of normal mammary epithelial cells. Our findings suggest that XN may be a promising natural compound to suppress the growth of luminal-type breast cancer.
O estrogen-receptor-a (ERa) plays a pivotal role in the development and progression of breast cancer. The current endocrine therapies for breast cancer are mainly based on targeting ERa signalling using selective ERa modulators (e.g., tamoxifen and raloxifene), ERa downregulators (e.g., fulvestrant), and aromatase inhibitor (AI) [1] [2] [3] . Of these treatments, tamoxifen, which inhibits breast cancer cell growth through the competitive binding of ERa, is a standard treatment offered to patients with ERa-positive breast cancer. However, tamoxifen treatment often fails, and patients succumb to recurrent, endocrine-resistant tumours 4, 5 . Moreover, AI, which blocks oestrogen (E2) synthesis, provides substantial clinical benefits, such as good efficacy, a significant increase in disease-free survival, and a prolonged time to disease recurrence in postmenopausal women with ERapositive breast cancer, compared with tamoxifen treatment. Nevertheless, some patients who have undergone AI treatment still relapse 6, 7 . The precise molecular events that determine alterations in the effectiveness of these endocrine therapies remain unknown.
We previously reported that the oncoprotein brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3) and tumour suppressor prohibitin 2 (PHB2) complex play a pivotal role in E2 signalling modulation in ERa-positive breast cancer 8, 9 . Namely, BIG3 binds PHB2, thereby inhibiting the E2-dependent suppressive ability of PHB2 and resulting in constitutive ERa activation. Considering these findings, strategies utilising the tumour suppressive activity of PHB2 upon its release from BIG3 by inhibitors of protein-protein interaction (PPI) may represent novel therapies for breast cancer, although PPI has been difficult to target with small molecules or synthetic peptide inhibitors. Indeed, we further demonstrated that a dominant-negative peptide, ERAP, which specifically disrupts the BIG3-PHB2 interaction, leads to the inhibition of multiple ERa-signalling pathways driving the growth of breast cancer by reactivating PHB2 tumour suppressive activity. However, because this peptide is difficult to use in clinical practice due to its limited stability, it is necessary to identify alternative longterm stable antagonistic compounds targeting the BIG3-PHB2 interaction.
Xanthohumol (XN: (2E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl) phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one), a prenylated chalcone present in hops (Humulus lupulus L.), has been shown to inhibit the growth of a wide variety of human cancer cell lines, including breast, ovarian, liver, colon, and prostate cancer cell lines 10, 11 . Most notably, several studies have reported that XN inhibits the proliferation of the breast cancer cell lines MCF-7 and SK-BR-3 both in vitro and in vivo [12] [13] [14] [15] [16] . However, these studies demonstrated an inhibition of cell proliferation in ERa-positive breast cancer cells in the absence of E2 stimulation or ERa-negative breast cancer cells. In fact, the precise mechanism of the antitumour effect of XN on E2-dependent growth in luminal-type breast cancer cells remains largely unknown. To clarify the precise mechanism of the antitumour effects of XN against breast cancer, we focused on the evidence that XN directly binds to the PHB2 protein 17 . Considering these and our previous findings, we hypothesised that the inhibition of the BIG3-PHB2 interaction by the direct binding of XN to PHB2 may lead to the suppression of constitutive ERa activation in breast cancer cells. Here, we found that XN inhibits E2/ERa signalling by reactivating the tumour-suppressive ability of PHB2, and its antitumour effect is more effective than that of ERAP.
Results
Xanthohumol inhibits the BIG3-PHB2 interaction and mediates the repression of multiple E2-induced activation events. Previous reports show that XN inhibits the proliferation of ERa-positive breast cancer cells [12] [13] [14] [15] [16] and specifically binds to the prohibitin proteins PHB1 and PHB2 17 . Moreover, we recently reported that BIG3-PHB2 complex formation plays a crucial role in ERapositive breast cancer cell growth 8, 9 . Considering these findings, we attempted to investigate the possibility of XN as an inhibitor targeting the BIG3-PHB2 interaction. Co-immunoprecipitation experiments revealed that XN dose-dependently inhibited the complex formation of endogenous BIG3 and PHB2 in the ERapositive breast cancer cell lines MCF-7 and KPL-3C, which highly express both BIG3 and PHB2 ( Fig. 1a and Supplementary Fig. S1a ). Similar results were obtained with ERAP treatment, a dominantnegative peptide inhibiting the BIG3-PHB2 interaction by its direct binding to PHB2 that we previously developed 9 ( Fig. 1a and Supplementary Fig. S1a ). We also demonstrated that XN directly bound to recombinant PHB2 protein in vitro ( Supplementary Fig.  S1b ). In addition, we found that XN inhibited the in vitro PHB2-ERAP interaction in a dose-dependent manner ( Supplementary Fig.  S1c ), suggesting the possibility that XN caused the specific inhibition of BIG3-PHB2 complex formation by its direct binding to PHB2.
We next investigated the subcellular distribution of endogenous PHB2 in ERa-positive breast cancer cells following XN treatment. The results showed that in the presence of E2, treatment with XN led to a decrease in cytoplasmic PHB2, thereby substantially increasing the amount of nuclear PHB2 (Fig. 1b, WCL) . Furthermore, coimmunoprecipitation experiments with an anti-ERa antibody indicated that the PHB2 released from BIG3 by XN treatment interacts with cytoplasmic and nuclear ERa in a dose-dependent manner (Fig. 1b , IP: ERa).
Next, we sought to elucidate the effect of XN on nuclear ERa function as a transcriptional factor. After validating E2-dependent PHB2 nuclear translocation by XN treatment using immunocytochemical approaches with MCF-7 and KPL-3C cells ( Fig. 1c and Supplementary Fig. S1d ), we analysed ERa transcriptional activity by luciferase reporter assays with oestrogen-responsive element (ERE) reporters. XN significantly inhibited E2-induced ERa transcriptional activity in a dose-dependent manner in MCF-7 and KPL-3C cells (minimum effective dose, 5 mM; Fig. 1d and Supplementary  Fig. S1e ).
We previously demonstrated that inhibiting the BIG3-PHB2 interaction interfered with E2-induced, non-genomic ERa activation pathways 9 . We next examined the effects of XN on the phosphorylation status of Akt and MAPK, which are the downstream signalling molecules of the non-genomic pathways [18] [19] [20] [21] . As expected, Akt (S473) and p42/44 MAPK (T202/Y204) phosphorylation levels were increased after 24 h of E2 stimulation in MCF-7 cells, whereas 30 mM XN treatment clearly abrogated the E2-induced phosphorylation levels of both proteins as well as that induced by ERAP treatment (Fig. 1e) . In addition, 30 mM XN treatment remarkably reduced the phosphorylation levels at all five sites (S104/S106, S118, S167, S305 and Y537) within ERa, which are involved in ERa transcriptional activity, DNA-binding, co-activator binding, protein stability and cell proliferation in ERa-positive breast cancer cells [22] [23] [24] [25] [26] [27] [28] [29] (Fig. 1e) . The amplitude of the suppression was comparable with that of the positive control ERAP. These results suggest that XN regulates ERa signalling, which is important for E2-dependent cell proliferation in ERa-positive breast cancer cells. Collectively, these findings indicate that XN treatment led to intrinsic PHB2 binding to ERa, thereby repressing multiple E2-induced activation events, including genomic and non-genomic ERa-activation, and ERa phosphorylation in breast cancer cells.
XN specifically suppresses the E2-dependent cell growth of breast cancer. To examine the effect of XN on breast cancer cell proliferation, we measured the E2-dependent cell growth of ERapositive breast cancer cell lines, MCF-7 or KPL-3C, with an MTT assay at 24 h after treatment with XN. The results showed that XN treatment significantly reduced the E2-stimulated cell growth in a dose-dependent manner (IC 50 5 7.3 mM and 8.2 mM in the MCF-7 and KPL-3C cells, respectively; Fig. 2a ). By contrast, 50 mM XN remarkably inhibited the cell proliferation of both MCF-7 and KPL-3C cells, indicating the inhibition of E2-independent cell growth ( Fig. 2a) . In fact, similar results were obtained with MCF-7 cell growth in the absence of E2 ( Supplementary Fig. S2a ), suggesting that 50 mM XN inhibits cell growth by independent mechanisms targeting the BIG3-PHB2 interaction. By contrast, compared with MCF-7 or KPL-3C cells, 30 mM XN had little effect on the growth of normal mammary epithelial MCF-10A cells that do not express ERa or BIG3 ( Fig. 2b and Supplementary Fig. S2b ). Accordingly, it must be noted that 50 mM XN treatment induced a non-specific inhibitory effect on the growth of MCF-10A cells. Furthermore, we also demonstrated that 30 mM XN treatment had no inhibitory effects on E2-induced growth of siRNA-mediated PHB2-depleted cells ( Supplementary Fig. S2c ), indicating that XN suppresses E2-induced cell growth through its specific inhibition of BIG3-PHB2 interaction. These results indicate that 30 mM XN specifically and completely inhibited multiple aspects of the E2/ERa-signalling network via the tumour-suppressive ability of endogenous PHB2 released from BIG3, resulting in complete suppression of E2-dependent breast cancer cell growth.
We next investigated the duration of the inhibitory effect of XN by an MTT assay. In contrast with ERAP, the inhibitory effect of XN on the growth of the MCF-7 and KPL-3C breast cancer cells was maintained for 96 h after XN treatment without affecting cell morphology ( Fig. 2c and Supplementary Figs. S2d-g ). In addition, XN also significantly suppressed E2-induced expression of the ERa-target genes TFF1 and CCND1 for 96 h after XN treatment (Fig. 2d) . Taken together, our findings strongly suggest that the inhibitory effect of XN on the responsiveness of ERa-positive breast cancer cells has much higher stability than that of ERAP.
Next, we examined the effects of XN on the cell cycle distribution of MCF-7 cells by flow cytometry and microscopy analyses. The population of cells in the G2/M phase increased after a 24 h E2 stimulation, whereas the population in the G1 phase, but not sub-G1 population, increased after 30 mM XN treatment, indicating that XN suppressed cell growth by inducing a G1 arrest and caused no cell phenotypic alterations, similar to ERAP (Fig. 3a,b; trast, high dose of XN treatment causes cell phenotypic alterations regardless of E2 stimulation ( Supplementary Fig. S3 ). Similarly, XN has been reported to induce apoptosis in several cancer cell lines, including leukemia, prostate cancer, and hepatoma cell lines 30 . We previously reported that XN acts as an autophagy modulator by directly binding to the N-domain of valosin-containing protein (VCP), which is essential for autophagosome-lysosome fusion and the formation of autolysosomes in cancer cells 17 . Therefore, we wished to clarify the effect of XN on VCP function in ERa-positive breast cancer cells. We first examined VCP expression in various cell lines, and found high expression of VCP in breast cancer cell lines as well as in colon and lung cancer cell lines and a mammary epithelial cell line (Fig. 3c) . Next, because XN was also reported to induce endoplasmic reticulum (ER) stress via inducing the loss of VCPmediated ER-associated degradation (ERAD) activity 17 , we examined the effect of XN treatment on the expression of CHOP and GRP78, ER stress-response genes. The results showed that 50 mM XN treatment, but not 30 mM XN, caused remarkable up-regulation of both genes at transcriptional levels regardless of E2 stimulation (Fig. 3d) . Furthermore, we examined whether the inhibitory effect of 30 mM XN treatment is due to its loss of VCP function. The results showed that 30 mM XN treatment could cause a complete suppression of E2-induced growth of VCP-depleted cells, suggesting that the inhibitory effect of 30 mM XN is not dependent on the loss of VCP The inhibitory actions of XN on ERa transcriptional activity were evaluated using luciferase assays. The data represent the mean 6 SE of three independent experiments (** P , 0.01, *** P , 0.001 in two-sided Student's t-test). (e) Immunoblot analyses were performed to evaluate the inhibitory effects of XN on E2-induced Akt (S473), MAPK (T202/Y204), and ERa (S104/S106, S118, S167, S305 and Y537) activities in MCF-7 cells. The blots were cropped, and the full-length blots were included in the supplementary information. function although 50 mM XN treatment might cause apoptosis through its inhibition of VCP function (Fig. 3e) . Taken together, our data clearly demonstrate that XN suppresses E2-induced cell growth via specific disruption of the BIG3-PHB2 interaction regardless of VCP function. ), or vehicle alone were administered daily by intraperitoneal injection for 36 days. The animals also received daily treatments of E2 (6 mg per day). Daily E2 treatment induced the time-dependent growth of KPL-3C tumours, whereas XN treatment caused a significant inhibition of E2-induced tumour growth comparable with that observed after ERAP treatment ( Fig. 4a and Supplementary Fig. S4a) . No toxicity or significant body weight changes were observed throughout these experiments (Supplementary Fig. S4b ). To clarify the mechanisms of the in vivo antitumour effect of XN, we first examined its effect on the BIG3-PHB2 interaction. Co-immunoprecipitation experiments in each tumour revealed that 1.0 mg kg 21 and 0.3 mg kg 21 XN treatment effectively inhibited the formation of the endogenous BIG3-PHB2 complex, resulting in nuclear translocation of PHB2 in tumours (Fig. 4b) . Substantially increased nuclear PHB2 staining was observed in tumours treated with XN in a dose-dependent manner by immunohistochemistry (Fig. 4c) . We next examined the effects of XN on the activation of the non-genomic ERa signalling pathway. As expected, considerable suppression of Akt and MAPK phosphorylation was observed in tumours treated with XN (Fig. 4d) , demonstrating that XN had potent in vivo antitumour activity. Furthermore, to evaluate the effect of XN treatment on the cell cycle in tumours, we investigated the expression of the proliferative markers, Ki67 and PCNA by immunohistochemistry 31 . Ki67 is known to be expressed in all phases of the active cell cycle (G1, S, G2 and M phase), and PCNA in most abundant during the S phase 32 . As shown in Fig. 4e , Ki67 was clearly detected in every tumour, whereas PCNA was not detected in tumours treated with 1.0 mg kg 21 XN or 14 mg kg 21 ERAP, indicating that XN treatment suppresses tumour growth by inducing G1-arrest. Collectively, these results suggest that XN acts as an effective therapeutic agent against ERa-positive breast cancer by inducing G1-arrest via targeting the BIG3-PHB2 interaction.
Discussion
Previous studies have shown that the BIG3-PHB2 complex plays a critical role in promoting breast cancer cell growth 8, 9 , and strategies capable of inhibiting this interaction may represent novel therapies The CHOP and GRP78 expression levels following XN treatment were evaluated using real-time PCR. The data represent the mean 6 SE of three independent experiments (* P , 0.05, ** P , 0.01, *** P , 0.001 in two-sided Student's t-test). (e) An MTT assay was performed to evaluate the inhibitory effect of XN on the E2-dependent growth of VCP-depleted cells. The data represent the mean 6 SE of three independent experiments (** P , 0.01, *** P , 0.001 in two-sided Student's t-test). for breast cancer. In this study, we demonstrated that a natural antitumour compound, XN, which binds to endogenous PHB2, prevented the BIG3-PHB2 interaction, thereby releasing PHB2 to inhibit both nuclear-and membrane-associated ERa activation. These data are in accordance with our previous observations that a dominant-negative peptide, ERAP targeting the BIG3-PHB2 interaction suppressed the growth of ERa-positive breast cancer cells 9 . Collectively, therapeutic strategies utilising the reactivation of PHB2 upon its PPI inhibitor-mediated release from BIG3 appeared to effectively treat luminal-type breast cancer cells, especially those with endocrine resistance. However, because the inhibitory effect of ERAP is maintained for only 24 h 9 , it is difficult to use in clinical practice. Therefore, we tested the inhibitory effect of XN, which directly binds to the PHB2 protein, as a selective antagonistic compound targeting the BIG3-PHB2 interaction and found that the inhibitory effect of XN demonstrated long-term stability was maintained for up to 96 h (Figs. 2c and d) . Moreover, no toxicity or significant body weight loss by daily intraperitoneal injection with effective doses for 36 days were observed. In addition, previous studies have shown that long-term treatment with XN causes no adverse effects on female mouse reproduction 32 . From a therapeutic perspective, XN targeting of the BIG3-PHB2 interaction provides excellent therapeutic indices with minimal off-target effects, thereby leading to better quality-of-life for patients with breast cancer.
Another interesting finding of this study is that 30 mM XN specifically inhibited multiple E2-induced cell growth pathways in breast cancer by targeting of the BIG3-PHB2 interaction despite the fact that XN is known to exert a broad spectrum of antitumour actions, such as apoptosis induction 10, 12, 29, 33 and NF-kB inhibition 34, 35 . In particular, we previously reported that XN bound directly to the N domain of VCP, thereby inducing endoplasmic reticulum (ER) stress via the loss of VCP-mediated ER-associated degradation (ERAD) activity 17 . Here, we here examined the effect of XN on ER stress induction and demonstrated that 50 mM XN, but not 30 mM XN, caused remarkable upregulation of the ER stress-response genes CHOP and GRP78 in breast cancer cells regardless of E2 stimulation (Fig. 3d) . These findings suggest that the antitumour effect of 30 mM XN is dependent on the inhibition of the BIG3-PHB2 interaction, but not on the loss of VCP function. However, high-dose (50 mM) XN treatment might cause loss of VCP function, thereby leading to the accumulation of unfolded proteins and resulting in ER-stress in cancer cells 36, 37 . Furthermore, we observed that 30 mM XN resulted in complete suppression of the E2-induced cell growth in VCP-depleted cells (Fig. 3e) . Taken together, XN (30 mM) treatment appears to be a natural antitumour compound targeting BIG3-PHB2 complex formation in breast cancer cells, although it will be necessary to clarify the effect of XN treatment on other binding partners involved in NF-kB signalling and apoptosis-related proteins.
Furthermore, we recently demonstrated that the combination of tamoxifen and ERAP induced more potent anti-tumour activity in vivo and in vitro compared with either treatment alone 9 . Thus, a combination of the current endocrine therapies and BIG3-PHB2 interaction inhibitors, such as XN or ERAP, may lead to more effective combined effects on the intrinsic and acquired endocrine resistance of breast cancer through the different modes of actions of these drugs. In conclusion, our findings show that the selective BIG3-PHB2 interaction inhibitor XN could completely suppress E2-dependent ERa activation and had growth-suppressive effects on breast cancer cells both in vitro and in vivo. These findings suggest that this BIG3-PHB2 interaction inhibitor may have great potential in the treatment of luminal type breast cancers, especially those with endocrine resistance. Cell lines and culture conditions. Human breast cancer cell lines (MCF-7, ZR-75-1, BT474, SK-BR-3, MDA-MB-453, MDA-MB-231), a mammary epitherial cell line (MCF-10A), colorectal cancer cell lines (HCT116, SW480), and epidermoid carcinoma cell line (A431) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). The KPL-3C cells were established, characterized, and kindly provided by Dr. Jun-ichi Kurebayashi (Kawasaki Medical School) 38 . . The cells were maintained at 37uC with 5% CO 2 . The next day, the medium was changed to phenol red-free DMEM/F12 (Life Technologies), supplemented with FBS, antibiotic/ antimycotic solution, NEAA, sodium pyruvate, and insulin. After 24 h, the cells were treated with 10 nM 17-oestradiol (E2, Sigma) 6 xanthohumol or peptides (e.g., ERAP).
Methods
Antibodies and immunoblot analyses. The anti-BIG3 monoclonal antibody was generated by Sigma-Aldrich (Tokyo, Japan). Briefly, a rat was immunised with purified His-tagged human BIG3 protein (459-572 aa). The iliac lymph nodes were collected and fused with myeloma cells, resulting in the formation of a hybridoma. Immunoblot analyses were performed as described previously 9 . After SDS-PAGE, the membranes blotted with proteins were blocked with 4% BlockAce solution (Dainippon Pharmaceutical, Osaka, Japan) for 1 h and then incubated with antibodies against the following proteins: BIG3 (151,000); PHB2 (151,000, Abcam, Cambridge, UK); ERa (SP-1, 15500, Thermo Fisher Scientific, Fremont, CA, USA); Akt, phospho-Akt (S473) (587F11, 151,000), p44/42 MAPK, phospho-p44/42 MAPK (T202/Y204) (151,000), VCP (valosin-containing protein) (15500), and a/b-tubulin (151,000) (Cell Signaling Technology, Danvers, MA, USA); b-actin (AC-15; 155,000) and LMNB1 (15100; Sigma) using standard procedures. All of the experiments were performed in triplicate at a minimum.
Immunoprecipitation. Immunoprecipitation analysis was performed as described previously 9 . The cell lysates were pre-cleared with normal IgG and rec-Protein G Sepharose 4B (Life Technologies) at 4uC for 3 h. Then, the supernatants were incubated with antibodies against BIG3 (5 mg) and ERa (5 mg) at 4uC for 12 h. Next, the antigen2antibody complexes were precipitated with rec-Protein G Sepharose 4B at 4uC for 1 h. The immunoprecipitated protein complexes were washed three times with lysis buffer. Subsequent SDS-PAGE and immunoblot analyses were performed as described above.
Direct binding of XN with recombinant PHB2 protein. Direct binding of XN to recombinant PHB2 protein was evaluated by XN-beads pull-down assay. The 3.6 mg of 6 x His-tagged recombinant PHB2 (His-PHB2) were incubated with 3 mL controlbeads or XN-beads together with 1 mg mL 21 BSA for 4 h. Then, the bound fractions were immunoblotted with anti-6xHis antibody (Takara, Shiga, Japan).
Ni-resin agarose pull-down assay. Binding inhibition of PHB2-ERAP interaction by XN was assayed by Ni-resin agarose pull-down. The binding assay was performed by mixing 0.27 nmole 6 x His-tagged recombinant PHB2, 0.27 nmole HA-ERAP, and 0.5 to 3 times moles of XN for 1 h at 4uC, followed by capturing Ni-NTA agarose (Qiagen, Hilden, Germany) for 2 h at 4uC. The bound fractions were washed with 5 mM imidazole five times and further eluted by SDS-sample buffer for immunoblot analyses.
Inhibition of the BIG3-PHB2 interaction by xanthohumol. The XN was isolated and purified as described previously 17 . XN was dissolved in dimethylsulphoxide (DMSO) at a concentration of 100 mmol L
21
, and then suspended in phenol red-free DMEM/F12 at the concentrations indicated. Treatment with 0.03% DMSO equivalent to 30 mM XN had no effect on E2-induced cell growth, ERa-target gene expression, Akt (S473), MAPK (T202/Y204), and ERa (S104/S106, S118, S167, S305 and Y537) activities, and BIG3-PHB2 interactions ( Supplementary Fig. S5a-d) . A dominant-negative peptide (ERAP; 11R-GGG-QMLSDLTLQLRQR), which was designed to specifically inhibit the BIG3-PHB2 interaction, was synthesised as described previously 9 and used as a positive control. To examine the effects of XN on the inhibition of endogenous BIG3-PHB2 complex formation, MCF-7 cells were treated with 10 nM E2 6 XN. The BIG3-PHB2 interactions were assessed 24 h later using co-immunoprecipitation followed by immunoblot analysis, as described above.
Nuclear/cytoplasmic fractionation. Nuclear and cytoplasmic fractions of MCF-7 cells were prepared using the NE-PER nuclear and cytoplasmic extraction reagent (Thermo Fisher Scientific) as described previously 9 . a/b-Tubulin and laminin B were used as loading controls for the cytoplasmic and nuclear fractions, respectively.
Immunocytochemical staining measurement of the nuclear-translocation of PHB2. MCF-7 cells were seeded at 5 3 10 4 cells per well in 8-well chambers (Laboratory-Tek II Chamber Slide System, Nalgene, Nunc International) for 48 h and then treated with E2 6 XN or ERAP for 24 h. The staining procedures were conducted as described previously 9 . 
